Amgen Inc. (AMGN)

184.44
0.39 0.21
NASDAQ : Health Technology
Prev Close 184.83
Open 184.60
Day Low/High 183.17 / 186.78
52 Wk Low/High 166.30 / 210.19
Volume 2.26M
Avg Volume 2.81M
Exchange NASDAQ
Shares Outstanding 609.94M
Market Cap 112.73B
EPS 12.70
P/E Ratio 14.73
Div & Yield 5.80 (2.96%)

Latest News

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia

Weekly Roundup

A quiet week offered a chance to get ready for volatility around the FOMC meeting and G-20 summit later this month.

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin

See How Amgen Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Amgen Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Amgen Inc is the #75 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

THOUSAND OAKS, Calif., June 12, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia,...

Weekly Roundup

Markets surge in face of multiple uncertainties.

Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 11:20 a.

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly's plan to eliminate pain could have farther reaching positive effects than just migraines.

Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients

Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients

Amgen releases data from its phase 1 study on an investigational bispecific T cell engager molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma.

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumour Types At ASCO 2019

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumour Types At ASCO 2019

Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO ® Investigational AMG 212 (Pasotuxizumab) Phase 1 Study Explores Use of BiTE Platform in a Solid...

Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) Inhibitor AMG 510 At ASCO 2019

Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) Inhibitor AMG 510 At ASCO 2019

AMG 510 is the First KRAS G12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research First-In-Human Results Show Preliminary Data and Anti-Tumour Activity in KRAS Mutant Solid Tumours MISSISSAUGA, ON, June 5, 2019 /CNW/ - Amgen (NASDAQ:...

As Markets Bounce Higher Tuesday, Updates on Several Portfolio Names in the News

The likely cause of the bounce is the oversold condition.

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Shares of Amgen rise after the company announces positive initial trial results from its experimental drug used to treat non-small-cell lung cancer patients.

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend

In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors FDA Grants AMG 510 Orphan Drug...

Proceed With Caution: Cramer's 'Mad Money' Recap (Friday 5/31/19)

Proceed With Caution: Cramer's 'Mad Money' Recap (Friday 5/31/19)

In light of Trump's latest action against Mexico, investors need to be even mor e careful.

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®

Weekly Roundup

Rough week for stocks capped by new front in tariff wars with Mexico.

Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.

Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution

Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution

THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ --  The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia,...

Amgen Joins With Community Oncology Networks For New Research Collaboration

Amgen Joins With Community Oncology Networks For New Research Collaboration

Amgen Community Oncology Research Collaborators (ACORC) Will Work to Expand Clinical Trial Access to Cancer Patients Treated Outside of Academic Centers

Weekly Roundup

Stocks falter on realization that trade war between U.S. and China is about more than soybeans.

Noteworthy Thursday Option Activity: AMGN, OMER, TLRD

Noteworthy Thursday Option Activity: AMGN, OMER, TLRD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Amgen Inc , where a total volume of 12,807 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.4% of AMGN's average daily trading volume over the past month, of 3.0 million shares.

Amgen Announces A Recommended Public Cash Offer To The Shareholders Of Nuevolution

Amgen Announces A Recommended Public Cash Offer To The Shareholders Of Nuevolution

THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia,...

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif.

Weekly Roundup

Markets' rocky week ends up close to where it began.

Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

That's Rule No. 5 of his '5 Rules for Trimming Your Winning Positions.'

China Winners and Losers: Cramer's 'Mad Money' Recap (Thursday 5/16/19)

China Winners and Losers: Cramer's 'Mad Money' Recap (Thursday 5/16/19)

Jim Cramer says Thursday's market action showed us a rally based on good old-fashioned earnings.

TheStreet Quant Rating: B (Buy)